For over two decades, a ‘treatment-risk paradox’ has been described in older adults with cardiovascular disease, with ...

or large non-ST elevation myocardial infarction (NSTEMI). Study subjects were randomized within 72 hours of PCI to either ...

Following cardiac catheterization, patients with ST-segment elevation myocardial infarction (STEMI) have a higher risk of short-term mortality than patients with non-STEMI (NSTEMI), who have a ...

In updated American recommendations for the management of acute coronary syndrome (ACS), bleeding reduction strategies on antiplatelet therapy are embraced, as are non-statin lipid-lowering therapies ...

For patients with either NSTEMI or STEMI, American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend that intravenous unfractionated heparin (UFH) be dosed by weight ...

More importantly, and less well described in the literature, is how this risk:benefit ratio plays out for patients with NSTEMI or for patients with ACS. As in the case of STEMI, the outcome of DES ...

Introduction: Recently, interest has been growing in lipoprotein(a) (Lp(a)) as an independent risk factor for cardiovascular diseases. European Society of Cardiology (ESC) recommends a single ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...

Individual patient data were obtained from three trials, including 9130 randomized patients with ACS: 3132 with ST-segment elevation myocardial infarction (STEMI); 3023 with non-STEMI (NSTEMI ...